Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions?

Abstract

It was not possible to identify LDE by impaired function of polymorphic CYPs.

Oral lichen planus to oral lichenoid lesions: Evolution or revolution

“…[ 9 ] Oral LDEs can appear at sites atypical for OLP, such as the palate or lip and unlike OLP, lesions tend to be unilateral. [ 4 5 26 27 28 ]…”

“…[ 16 28 ] OLLs share common clinical and histological features. [ 1 4 28 ] Despite the reported differences between idiopathic LP and LDE, the WHO “gold standard” criteria for LP does not distinguish between the two conditions. [ 12 21 26 30 ]…”

“…Furthermore, it is difficult to establish a causal relation to drugs as the majority of middle-aged and older persons are exposed to drugs and polypharmacy on a daily basis for treating systemic disease. [ 28 ]…”

Adverse Immunologically Mediated Oral Mucosal Reactions to Systemic Medication: Lichenoid Tissue Reaction/Interface Dermatitis-Stomatitis, Autoimmune Vesiculobullous Disease, and IgE-Dependent and Immune Complex Reactions

“…To complicate matters, older subjects are often taking several drugs, each of which may be inducing an immune reaction, which may be affected by drug interaction, and changes in the drug regimen create uncertainty as to whether currently or previously used drugs may be implicated. Therefore, reaching a conclusion about whether an immune-mediated reaction is drug-induced or is idiopathic can be difficult if not impossible [ 12 , 13 , 16 , 17 ]. Yet another complication is the possibility of exposure to industrial, occupational, or even household agents that can induce or trigger immune responses, thus influencing the pathogenesis and course of immune-mediated oral conditions [ 18 ].…”

Use of systemic medication in patients with oral lichen planus – a possible association with hypothyroidism

“…Several studies aiming to explore a possible association between medication and OLP often conclude that the number of patients has been too small to show any subgroups of drug-induced OLP (Potts et al, 1987;Kragelund et al, 2010;Paulusova et al, 2010). In the last decade, our group has systematically used electronic tools to register information on OLP (Jontell et al, 2005).…”